Pfizer Inc. Announces Discontinuation of Weight Management Pill Development

In a significant development, Pfizer Inc. revealed on Monday its decision to stop the development of danuglipron, its daily pill aimed at chronic weight management. This decision comes after a trial participant suffered from drug-induced liver injury, marking a setback in the quest for effective obesity treatments.

Details of the Incident

The company detailed that the participant involved in one of the dose-optimization studies experienced an elevation in liver enzymes. Fortunately, the individual did not exhibit any liver-related symptoms or side effects, and enzyme levels normalized upon discontinuation of the pill.

Pfizer's Commitment to Addressing Obesity

Despite this hurdle, Pfizer remains committed to tackling cardiovascular and metabolic diseases, including obesity. Chris Boshoff, Pfizer's Chief Scientific Officer and President of R&D, emphasized the company's dedication to advancing a pipeline of investigational treatments. "We plan to continue applying our global capabilities to advance treatments that fill critical gaps in patient care, including our oral GIPR antagonist candidate and other earlier obesity programs," Boshoff stated.